(RTTNews) – Immuneering Corp. (IMRX), a late-stage clinical oncology company, announced that it is on track to dose the first patient in its planned phase 3 trial of Atebimetinib in first-line metastatic pancreatic cancer patients in mid-2026.
The planned global Phase 3 registrational trial, dubbed MAPKeeper 301, will evaluate Atebimetinib (320 mg QD) in combination with modified gemcitabine and nab-paclitaxel (mGnP), compared with gemcitabine and nab-paclitaxel (GnP) alone.
A total of approximately 510 patients are expected to be enrolled in the Phase 3 trial.
The company has s
